The NDA for Furoscix has been accepted for filing by the FDA and under the PDUFA, the FDA has set an action date of June 23, 2018.
| |
| [02-November-2017] |
| BURLINGTON, Mass., Nov. 2, 2017 /PRNewswire/ -- scPharmaceuticals, a pharmaceutical company focused on developing and commercializing products that have the potential to transform the way therapy is delivered, advance patient care and reduce healthcare costs, today announced that the 505(b)(2) New Drug Application (NDA) for Furoscix has been accepted for filing by the U.S. Food and Drug Administration (FDA). Under the Prescription Drug User Fee Act (PDUFA), the FDA has set an action date of June 23, 2018. About scPharmaceuticals scPharmaceuticals is a clinical-stage pharmaceutical company focused on developing and commercializing products that have the potential to transform the way therapy is delivered, advance patient care and reduce healthcare costs. Our proprietary platform is designed to enable the subcutaneous administration of therapies that have previously been limited to intravenous (IV) delivery. View original content with multimedia:http://www.prnewswire.com/news-releases/scpharmaceuticals-announces-fda-acceptance-of-nda-for-furoscix-subcutaneous-furosemide-300548066.html SOURCE scPharmaceuticals, Inc. |
